R&D Update on April 10, 2014 in New York

• Innate Pharma will update investors and analysts on its pipeline and strategy

• The Company will present the clinical development plan of IPH2201 NKG2A checkpoint inhibitor, expected to start Phase II in 2014

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Company will host a Research and Development Update on April 10, 2014, in New York, from 8am to 1pm.

At this R&D Update, Innate Pharma’s management team will review and discuss with attendees Innate Pharma’s pipeline and strategy. The Company will present the clinical development plan for IPH2201, a first-in-class NKG2A checkpoint inhibitor, which Phase II in oncology is expected to start in 2014.

Attendance is by invitation only and subject to room capacity.

The R&D Update will be live webcasted and also available after the event at the following link:

http://psav.rampard.com/20140410/